The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia-Reference-Cited by-同舟云学术

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia

Published:2018-10 Issue: Volume:141 Page:260-271
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Flores Andrew J.,Bartlett Mitchell J.,Root Brandon K.,Parent Kate L.,Heien Michael L.,Porreca Frank,Polt Robin,Sherman Scott J.,Falk Torsten

Funder

American Parkinson's Disease Association, the Jackson Fellowship to the University of Arizona Department of Neurology

Office of Naval Research

National Science Foundation

National Institutes of Health

ARCS Foundation

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference71 articles.

1. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model;Bartlett;Neurosci. Lett.,2016

2. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys;Bezard;Neurobiol. Dis.,2001

3. Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats;Billet;Exp. Neurol.,2012

4. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability;Bilsky;J. Med. Chem.,2000

5. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa;Bordet;Proc. Natl. Acad. Sci. U. S. A.,1997

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The angiotensin (1–7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation;Experimental Neurology;2024-11

2. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model;Neuropharmacology;2024-10

3. Neuroinflammation and Dyskinesia: A Possible Causative Relationship?;Brain Sciences;2024-05-20

4. Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion;Brain Research;2023-12

5. Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation;Frontiers in Immunology;2023-10-04